

PATENT

S02676/08



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HANSON ET AL

SERIAL NUMBER: 09/996,345

FILED: 28 NOV 01

GROUP ART UNIT: 1621

EXAMINER: M.L. SHIPPEN

DATE: 23 DEC 03

RECEIVED

DEC 31 2003

TECH CENTER 1600/2900

TITLE: USE OF PROPARGYL GLYCINE AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF RENAL FAILURE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner of Patents and Trademarks,
Alexandria, VA 22313-1450 on 23 DEC 03

J. Timothy Keane

Registration No. 27,808

Date:

23 Dec 03

TERMINAL DISCLAIMER

Commissioner of Patents and Trademarks
Alexandria, VA 22313-1450

Sir:

This Substitute Terminal Disclaimer replaces the Terminal Disclaimer filed on 13 March 2003.

I, J. Timothy Keane, represent that I am the attorney of record for this invention, that Pharmacia Corporation, parent company of G.D. Searle & Co., P.O. Box 5110, Chicago, Illinois 60680, a corporation in the State of Delaware, owns all of the right, title and interest in the above-identified application Serial No. 09/996,345, which is a divisional of Serial No. 09/479,280 filed January 6, 2000, which issued on January 29, 2002 as U.S. Patent No. 6,342,624, which is a continuation of application Serial No. 09/969,522 filed on November 3, 1997, which is now abandoned, which is a continuation of application Serial No. 08/771,334 filed January 16, 1996, which is now abandoned, which is a continuation of 08/586,440, filed January 16, 1996, which is now abandoned, which is a continuation of application Serial No. 08/199,237 filed February 28, 1994, now U.S. Patent No. 5,484,812, which is a continuation of 07/784,272, filed on October 29, 1991, now U.S. Patent No. 5,223,535.

Your petitioner, J. Timothy Keane, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 for U.S. Patent No. 6,342,624, and hereby agrees enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to U.S. Patent No. 6,342,624, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer petitioner does not disclaim any terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full or extended statutory term as defined in 35 U.S.C. 154 to 156 and 173 in the event that U.S. Patent No. 6,342,624 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Further, the petitioner does not disclaim any right to extend the term of any patent issued for the above-identified application under 35 U.S.C. 156 from the date of expiration for such patent as is imposed by this terminal disclaimer.

The evidentiary documents accompanying or referred to in the Instant Terminal Disclaimer have been reviewed by the undersigned and it is certified that to the best of my knowledge and belief, title is in the assignee.

Signature



PHARMACIA CORPORATION
of Pfizer Inc.
Global Patent Department
P.O. Box 1027
Chesterfield, MO 63006

Dated:

23 December 2003

J. Timothy Keane
Attorney of Record
Reg. No. 27,808
Tel: 314-274-9090